id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id FDA-2016-N-3120-0588,FDA,FDA-2016-N-3120,Joint Statement on Proposed Hearing Dates,Other,Statement,2026-10-08T04:00:00Z,2026,10,2026-10-08T04:00:00Z,,2026-10-09T00:55:05Z,,0,0,09000064b9653e97 FDA-2016-N-3120-0589,FDA,FDA-2016-N-3120,Order Scheduling Hearing,Other,Order,2026-10-08T04:00:00Z,2026,10,2026-10-08T04:00:00Z,,2026-10-09T00:55:11Z,,0,0,09000064b9653f5d FDA-2016-N-3120-0586,FDA,FDA-2016-N-3120,Notice of Appearance,Other,Appearance Request,2026-09-28T04:00:00Z,2026,9,2026-09-28T04:00:00Z,,2026-09-28T19:40:28Z,,0,0,09000064b95d4266 FDA-2016-N-3120-0587,FDA,FDA-2016-N-3120,Order Summarizing Prehearing Conference and Order Granting 90-Day Extension,Other,Order,2026-09-28T04:00:00Z,2026,9,2026-09-28T04:00:00Z,,2026-09-28T22:54:46Z,,0,0,09000064b95e0d58 FDA-2016-N-3120-0585,FDA,FDA-2016-N-3120,Notice of Participation,Other,Public Participation,2026-09-15T04:00:00Z,2026,9,2026-09-15T04:00:00Z,,2026-09-24T18:45:10Z,,0,0,09000064b95549cd FDA-2016-N-3120-0584,FDA,FDA-2016-N-3120,Notice of Entry of Appearance,Other,Appearance Request,2026-09-15T04:00:00Z,2026,9,2026-09-15T04:00:00Z,,2026-09-15T19:09:30Z,,0,0,09000064b95549cb FDA-2016-N-3120-0583,FDA,FDA-2016-N-3120,Notice of Participation,Other,Public Participation,2026-09-11T04:00:00Z,2026,9,2026-09-11T04:00:00Z,,2026-09-11T22:35:53Z,,0,0,09000064b9522622 FDA-2016-N-3120-0578,FDA,FDA-2016-N-3120,Notice of Entry of Appearance,Other,Appearance Request,2026-09-10T04:00:00Z,2026,9,2026-09-10T04:00:00Z,,2026-09-10T22:43:19Z,,0,0,09000064b9511033 FDA-2016-N-3120-0577,FDA,FDA-2016-N-3120,Notice of Entry of Appearance,Other,Appearance Request,2026-09-10T04:00:00Z,2026,9,2026-09-10T04:00:00Z,,2026-09-10T17:15:56Z,,0,0,09000064b95092a8 FDA-2016-N-3120-0579,FDA,FDA-2016-N-3120,Notice of Entry of Appearance,Other,Appearance Request,2026-09-10T04:00:00Z,2026,9,2026-09-10T04:00:00Z,,2026-09-10T22:45:00Z,,0,0,09000064b9513d92 FDA-2016-N-3120-0581,FDA,FDA-2016-N-3120,Notice of Entry of Appearance,Other,Appearance Request,2026-09-10T04:00:00Z,2026,9,2026-09-10T04:00:00Z,,2026-09-10T22:46:22Z,,0,0,09000064b9513d93 FDA-2016-N-3120-0576,FDA,FDA-2016-N-3120,Notice of Entry of Appearance,Other,Appearance Request,2026-09-10T04:00:00Z,2026,9,2026-09-10T04:00:00Z,,2026-09-10T15:33:22Z,,0,0,09000064b94cb9cd FDA-2016-N-3120-0582,FDA,FDA-2016-N-3120,Notice of Entry of Appearance,Other,Appearance Request,2026-09-10T04:00:00Z,2026,9,2026-09-10T04:00:00Z,,2026-09-10T22:49:25Z,,0,0,09000064b95110b9 FDA-2016-N-3120-0580,FDA,FDA-2016-N-3120,Notice of Entry of Appearance,Other,Appearance Request,2026-09-10T04:00:00Z,2026,9,2026-09-10T04:00:00Z,,2026-09-10T22:45:35Z,,0,0,09000064b95134a7 FDA-2016-N-3120-0575,FDA,FDA-2016-N-3120,Notice of Entry of Appearance,Other,Appearance Request,2026-09-08T04:00:00Z,2026,9,2026-09-08T04:00:00Z,,2026-09-08T22:06:57Z,,0,0,09000064b94fa7bb FDA-2016-N-3120-0574,FDA,FDA-2016-N-3120,Notice of Entry of Appearance,Other,Appearance Request,2026-09-04T04:00:00Z,2026,9,2026-09-04T04:00:00Z,,2026-09-04T17:54:56Z,,0,0,09000064b94c37a3 FDA-2016-N-3120-0573,FDA,FDA-2016-N-3120,Notice of Entry of Appearance,Other,Appearance Request,2026-09-03T04:00:00Z,2026,9,2026-09-03T04:00:00Z,,2026-09-10T20:51:09Z,,0,0,09000064b94c5305 FDA-2016-N-3120-0570,FDA,FDA-2016-N-3120,"Kremers Urban Pharmaceuticals, Inc.; Grant of Hearing Request Regarding a Proposal To Withdraw Approval of an Abbreviated New Drug Application for Extended-Release Methylphenidate Tablets",Notice,Withdrawal,2026-08-13T04:00:00Z,2026,8,2026-08-13T04:00:00Z,2026-10-14T03:59:59Z,2026-10-14T09:00:39Z,2026-16536,0,0,09000064b943bc08 FDA-2016-N-3120-0572,FDA,FDA-2016-N-3120,"Reference 1 - U.S. Department of Health and Human Services, Departmental Appeals Board, Civil Remedies Division, Kremers Urban Pharmaceuticals, Inc. Proposal to Withdraw Approval of an Abbreviated New Drug Application for Extended Release Methylphenidate Tablets, Case Development Order [Civil Remedies Division Procedures, March 28, 2016], August 13, 2026.",Supporting & Related Material,Background Material,2026-08-13T04:00:00Z,2026,8,,,2026-08-25T19:18:02Z,,0,0,09000064b943af66 FDA-2016-N-3120-0569,FDA,FDA-2016-N-3120,Methyl SOF (ANDA 091695) 022726,Other,Memorandum,2026-03-02T05:00:00Z,2026,3,2026-03-02T05:00:00Z,,2026-03-02T17:14:36Z,,0,0,09000064b91e2ceb FDA-2016-N-3120-0567,FDA,FDA-2016-N-3120,5_Kremers Hearing Request_2016-N-3120_CDER analysis,Other,Additional Information,2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T20:27:22Z,,0,0,09000064b91d86ba FDA-2016-N-3120-0566,FDA,FDA-2016-N-3120,4_Kremers Hearing Request_2016-N-3120_CDER 12.85 statement,Other,Additional Information,2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T20:26:54Z,,0,0,09000064b91d86b8 FDA-2016-N-3120-0561,FDA,FDA-2016-N-3120,1d_Jan 2020 APSARD mtg_prsnt-Gomeni 20200118,Other,Presentation,2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T20:26:16Z,,0,0,09000064b91d86ae FDA-2016-N-3120-0564,FDA,FDA-2016-N-3120,2a_Kremers_Dkt FDA-2016-N-3120_09 11 25_enclosure,Other,Memorandum,2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T20:26:41Z,,0,0,09000064b91d86b4 FDA-2016-N-3120-0559,FDA,FDA-2016-N-3120,1b_Jan 2020 APSARD mtg_prsnt-Babiskin 20200118,Other,Presentation,2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T20:25:58Z,,0,0,09000064b91d8096 FDA-2016-N-3120-0558,FDA,FDA-2016-N-3120,1a_data description_PK updated_and noting withholding,Other,Letter(s),2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T20:25:48Z,,0,0,09000064b91d8094 FDA-2016-N-3120-0557,FDA,FDA-2016-N-3120,1_Kremers_Dkt FDA-2016-N-3120_11 29 21,Other,Letter(s),2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T20:25:36Z,,0,0,09000064b91d8092 FDA-2016-N-3120-0563,FDA,FDA-2016-N-3120,2_Kremers_Dkt FDA-2016-N-3120_09 11 25,Other,Letter(s),2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T20:26:33Z,,0,0,09000064b91d86b2 FDA-2016-N-3120-0565,FDA,FDA-2016-N-3120,3_Methylphenidate SOF (ANDA 091695) 021226,Other,Letter(s),2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T20:26:47Z,,0,0,09000064b91d86b6 FDA-2016-N-3120-0568,FDA,FDA-2016-N-3120,6_Kremers Hearing Request_2016-N-3120_draft proposed order,Other,Additional Information,2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T20:27:31Z,,0,0,09000064b91d86bc FDA-2016-N-3120-0560,FDA,FDA-2016-N-3120,1c_Jan 2020 APSARD mtg_prsnt-AChildress 20200115,Other,Presentation,2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T20:26:08Z,,0,0,09000064b91d8098 FDA-2016-N-3120-0562,FDA,FDA-2016-N-3120,1e_Jan 2020 APSARD mtg_prsnt-Spencer 20200118,Other,Additional Information,2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T20:26:25Z,,0,0,09000064b91d86b0 FDA-2016-N-3120-0549,FDA,FDA-2016-N-3120,A091695N000Min-2_Redacted,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:47:25Z,,0,0,0900006484a5f6c8 FDA-2016-N-3120-0545,FDA,FDA-2016-N-3120,091695 Kremers Advice Letter EU Dat,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:41:52Z,,0,0,0900006484a5f69f FDA-2016-N-3120-0547,FDA,FDA-2016-N-3120,2015-9-22_Kremers Methylphenidate HCl ER Tablets-ANDA 091695,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:43:39Z,,0,0,0900006484a5f6c4 FDA-2016-N-3120-0551,FDA,FDA-2016-N-3120,data description,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:49:25Z,,0,0,0900006484a5f6ca FDA-2016-N-3120-0532,FDA,FDA-2016-N-3120,0044_m1_Gen Corres_Summary Slides,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:01:14Z,,0,0,0900006484a5f5f1 FDA-2016-N-3120-0533,FDA,FDA-2016-N-3120,0048_m1_Gen Corres_Mtg Minutes_July,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:02:40Z,,0,0,0900006484a5f5f2 FDA-2016-N-3120-0539,FDA,FDA-2016-N-3120,2015-5-05_91695 MR denied,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:34:10Z,,0,0,0900006484a5f5f8 FDA-2016-N-3120-0546,FDA,FDA-2016-N-3120,2016-10-17 091695 Kremers Advice Letter (2),Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:42:57Z,,0,0,0900006484a5f6a1 FDA-2016-N-3120-0531,FDA,FDA-2016-N-3120,0044_m1_Gen Corres_Mtg Agenda,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:59:02Z,,0,0,0900006484a5f5f0 FDA-2016-N-3120-0515,FDA,FDA-2016-N-3120,0007_m5_study r10-0827_case report forms,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:40:34Z,,0,0,0900006484a5cf70 FDA-2016-N-3120-0518,FDA,FDA-2016-N-3120,0007_m5_study r10-0828_CSR,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:43:47Z,,0,0,0900006484a5cf75 FDA-2016-N-3120-0536,FDA,FDA-2016-N-3120,2014-11-12_ANDA 091695,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:07:47Z,,0,0,0900006484a5f5f7 FDA-2016-N-3120-0529,FDA,FDA-2016-N-3120,0043_m1_correction of conv error,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:57:16Z,,0,0,0900006484a5cfbb FDA-2016-N-3120-0552,FDA,FDA-2016-N-3120,Full Protocol,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:50:45Z,,0,0,0900006484a5f6cb FDA-2016-N-3120-0554,FDA,FDA-2016-N-3120,LCMS_ValidationReport_Methylphenidate_DBS_10uL,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:53:40Z,,0,0,0900006484a5f6fe FDA-2016-N-3120-0543,FDA,FDA-2016-N-3120,2015-9-9_091695 7-20-15 Meeting Minutes,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:40:10Z,,0,0,0900006484a5f69d FDA-2016-N-3120-0524,FDA,FDA-2016-N-3120,0042_M1_ba be studies_req for mtg,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:50:50Z,,0,0,0900006484a5cfa2 FDA-2016-N-3120-0514,FDA,FDA-2016-N-3120,0007_m5_r10-0828_csr,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:39:40Z,,0,0,0900006484a5cf68 FDA-2016-N-3120-0519,FDA,FDA-2016-N-3120,0034_Response to Information Request,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:44:51Z,,0,0,0900006484a5cf76 FDA-2016-N-3120-0521,FDA,FDA-2016-N-3120,0038_m1_General Correspondence,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:46:57Z,,0,0,0900006484a5cf8b FDA-2016-N-3120-0553,FDA,FDA-2016-N-3120,LCMS_ValidationReport_Methylphenidate_DBS_5uL,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:52:38Z,,0,0,0900006484a5f6f9 FDA-2016-N-3120-0556,FDA,FDA-2016-N-3120,RE_ ANDA 91695 Methylphenidate ER Tablets,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:55:26Z,,0,0,0900006484a5f71d FDA-2016-N-3120-0525,FDA,FDA-2016-N-3120,0042_M2_summary of be studies,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:51:49Z,,0,0,0900006484a5cfa3 FDA-2016-N-3120-0534,FDA,FDA-2016-N-3120,2014-5-2_correspondence_20dec2013-email,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:06:14Z,,0,0,0900006484a5f5f5 FDA-2016-N-3120-0544,FDA,FDA-2016-N-3120,2015-9-9_A091695N000Min,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:41:01Z,,0,0,0900006484a5f69e FDA-2016-N-3120-0528,FDA,FDA-2016-N-3120,0042_m5_csr,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:56:11Z,,0,0,0900006484a5cfb9 FDA-2016-N-3120-0548,FDA,FDA-2016-N-3120,91695 - 11-13-2014,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:46:30Z,,0,0,0900006484a5f6c5 FDA-2016-N-3120-0526,FDA,FDA-2016-N-3120,0042_m5_2015-3768 and 3769 -be_case report forms,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:53:09Z,,0,0,0900006484a5cfa8 FDA-2016-N-3120-0527,FDA,FDA-2016-N-3120,0042_m5_2015-3769-ba,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:54:42Z,,0,0,0900006484a5cfaa FDA-2016-N-3120-0517,FDA,FDA-2016-N-3120,0007_m5_study r10-0828_case report forms,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:43:00Z,,0,0,0900006484a5cf74 FDA-2016-N-3120-0541,FDA,FDA-2016-N-3120,2015-5-11_da-ku-correspondence-11may2015,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:37:02Z,,0,0,0900006484a5f69a FDA-2016-N-3120-0516,FDA,FDA-2016-N-3120,0007_m5_study r10-0827_CSR,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:41:34Z,,0,0,0900006484a5cf71 FDA-2016-N-3120-0530,FDA,FDA-2016-N-3120,0043_m2_pk sum rep,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:58:14Z,,0,0,0900006484a5ef4d FDA-2016-N-3120-0537,FDA,FDA-2016-N-3120,0042_m5_2015_3768 be_CSR,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:32:55Z,,0,0,0900006484a5cfa5 FDA-2016-N-3120-0535,FDA,FDA-2016-N-3120,2014-5-2_correspondence_26feb2014-email,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:06:57Z,,0,0,0900006484a5f5f6 FDA-2016-N-3120-0522,FDA,FDA-2016-N-3120,0042_2015_3768 ba,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:47:43Z,,0,0,0900006484a5cf92 FDA-2016-N-3120-0513,FDA,FDA-2016-N-3120,0007_m5_ba be,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:39:35Z,,0,0,0900006484a5cf67 FDA-2016-N-3120-0538,FDA,FDA-2016-N-3120,0050_m1_Gen Corres_Sept 2015,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:33:48Z,,0,0,0900006484a5f5f4 FDA-2016-N-3120-0540,FDA,FDA-2016-N-3120,2015-5-5_Meeting Request for ANDA 091695,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:36:01Z,,0,0,0900006484a5f699 FDA-2016-N-3120-0542,FDA,FDA-2016-N-3120,2015-6-26_ANDA 91695 Meeting Request Granted Letter,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:38:16Z,,0,0,0900006484a5f69b FDA-2016-N-3120-0523,FDA,FDA-2016-N-3120,0042_2015_3769 be_CSR,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:49:55Z,,0,0,0900006484a5cf94 FDA-2016-N-3120-0520,FDA,FDA-2016-N-3120,0039_m1_Gen Corres_Req for Mtg,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T20:46:11Z,,0,0,0900006484a5cf84 FDA-2016-N-3120-0550,FDA,FDA-2016-N-3120,ANDA 091695 Methylphenidate TSI 1349 Summary,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:48:21Z,,0,0,0900006484a5f6c9 FDA-2016-N-3120-0555,FDA,FDA-2016-N-3120,Letter Beers to Scheineson 5 14 19,Supporting & Related Material,Background Material,2021-03-04T05:00:00Z,2021,3,,,2021-03-04T21:54:34Z,,0,0,0900006484a5f6ff FDA-2016-N-3120-0509,FDA,FDA-2016-N-3120,0000_m5_5312 ba-be case rep forms,Supporting & Related Material,Background Material,2021-03-03T05:00:00Z,2021,3,,,2021-03-03T18:10:15Z,,0,0,0900006484a5cf4c FDA-2016-N-3120-0511,FDA,FDA-2016-N-3120,0007_m2_summary-biopharm,Supporting & Related Material,Background Material,2021-03-03T05:00:00Z,2021,3,,,2021-03-03T18:12:23Z,,0,0,0900006484a5cf4e FDA-2016-N-3120-0508,FDA,FDA-2016-N-3120,0000_M5_5311bioavailiabilty_bioequivalence,Supporting & Related Material,Background Material,2021-03-03T05:00:00Z,2021,3,,,2021-03-03T18:09:07Z,,0,0,0900006484a5cf4b FDA-2016-N-3120-0507,FDA,FDA-2016-N-3120,0000_M3_Des and Comp of Drug Product,Supporting & Related Material,Background Material,2021-03-03T05:00:00Z,2021,3,,,2021-03-03T18:05:19Z,,0,0,0900006484a5cf47 FDA-2016-N-3120-0510,FDA,FDA-2016-N-3120,0007_M1,Supporting & Related Material,Background Material,2021-03-03T05:00:00Z,2021,3,,,2021-03-03T18:11:26Z,,0,0,0900006484a5cf4d FDA-2016-N-3120-0512,FDA,FDA-2016-N-3120,0007_m3_desc and comp,Supporting & Related Material,Background Material,2021-03-03T05:00:00Z,2021,3,,,2021-03-03T18:17:44Z,,0,0,0900006484a5cf51 FDA-2016-N-3120-0505,FDA,FDA-2016-N-3120,Letter Beers to Scheineson 3 7 19,Other,Letter(s),2019-04-12T04:00:00Z,2019,4,2019-04-12T04:00:00Z,,2019-04-12T15:51:46Z,,0,0,0900006483b8b981 FDA-2016-N-3120-0506,FDA,FDA-2016-N-3120,270_091695_Memo correction 11282018,Supporting & Related Material,Background Material,2019-04-12T04:00:00Z,2019,4,,,2019-04-12T15:52:48Z,,0,0,0900006483b8b7ec FDA-2016-N-3120-0501,FDA,FDA-2016-N-3120,"Cover Letter for Supplemental Materials re Request for Hearing from Kremers Urban Pharmaceuticals, Inc. (Alston & Bird)",Other,Letter(s),2018-05-07T04:00:00Z,2018,5,2018-05-07T04:00:00Z,,2018-05-07T12:22:50Z,,0,0,0900006483235fba FDA-2016-N-3120-0500,FDA,FDA-2016-N-3120,Letter from Kremers Urban Pharmaceuticals Inc. (Alston & Bird) to FDA DDM,Other,Letter(s),2018-05-03T04:00:00Z,2018,5,2018-05-03T04:00:00Z,,2018-05-03T19:34:11Z,,0,0,09000064832286a8 FDA-2016-N-3120-0495,FDA,FDA-2016-N-3120,"""265_202608_Fasting Reanalysis"" (Fed)",Supporting & Related Material,Background Material,2018-04-03T04:00:00Z,2018,4,,,2018-04-03T14:45:54Z,,0,0,090000648302cdd9 FDA-2016-N-3120-0494,FDA,FDA-2016-N-3120,Letter Beers to Scheineson 2 13 18,Other,Letter(s),2018-04-03T04:00:00Z,2018,4,2018-04-03T04:00:00Z,,2018-04-03T14:44:23Z,,0,0,090000648302cdd6 FDA-2016-N-3120-0498,FDA,FDA-2016-N-3120,268_091695_Fed Reanalysis,Supporting & Related Material,Background Material,2018-04-03T04:00:00Z,2018,4,,,2018-04-03T14:47:13Z,,0,0,090000648302cddd FDA-2016-N-3120-0497,FDA,FDA-2016-N-3120,267_091695_Fasting Reanalysis,Supporting & Related Material,Background Material,2018-04-03T04:00:00Z,2018,4,,,2018-04-03T14:46:52Z,,0,0,090000648302cddc FDA-2016-N-3120-0496,FDA,FDA-2016-N-3120,"""266_202608_Fed Reanalysis"" (Fasting)",Supporting & Related Material,Background Material,2018-04-03T04:00:00Z,2018,4,,,2018-04-03T14:46:31Z,,0,0,090000648302cddb FDA-2016-N-3120-0445,FDA,FDA-2016-N-3120,"Reference 77 Massachusetts General Hospital, PK/PD Pediatric ADHD Classroom Study. NCT02536105 re Request for Hearing from Kremers Urban Pharmaceuticals, Inc. (Alston & Bird)",Supporting & Related Material,Reference (external attachments),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T19:16:36Z,,0,0,0900006482d154cd FDA-2016-N-3120-0469,FDA,FDA-2016-N-3120,"Reference 101 Shram et al (2012). See Abstract Title re Request for Hearing from Kremers Urban Pharmaceuticals, Inc. (Alston & Bird)",Supporting & Related Material,Reference (external attachments),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T21:14:23Z,,0,0,0900006482d154e5 FDA-2016-N-3120-0475,FDA,FDA-2016-N-3120,"Reference 107 Stein et al (2003). See Abstract Title re Request for Hearing from Kremers Urban Pharmaceuticals, Inc. (Alston & Bird)",Supporting & Related Material,Reference (external attachments),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T21:38:24Z,,0,0,0900006482d154eb FDA-2016-N-3120-0489,FDA,FDA-2016-N-3120,"Reference 121 Wigal, et al (1998). Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharm Bull, 34(1), 47-56. re Request for Hearing from Kremers Urban Pharmaceuticals, Inc. (Alston & Bird)",Supporting & Related Material,Reference (external attachments),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T22:08:06Z,,0,0,0900006482d154f9 FDA-2016-N-3120-0484,FDA,FDA-2016-N-3120,"Reference 116 Vitiello et al (2001). See Abstract Title re Request for Hearing from Kremers Urban Pharmaceuticals, Inc. (Alston & Bird)",Supporting & Related Material,Reference (external attachments),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T22:01:03Z,,0,0,0900006482d154f4 FDA-2016-N-3120-0483,FDA,FDA-2016-N-3120,"Reference 115 United States Pharmacopeia (USP), Convention (2017). Methylphenidate Hydrochloride Monograph re Request for Hearing from Kremers Urban Pharmaceuticals, Inc. (Alston & Bird)",Supporting & Related Material,Reference (external attachments),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T21:58:35Z,,0,0,0900006482d154f3 FDA-2016-N-3120-0446,FDA,FDA-2016-N-3120,"Reference 78 Micheal & Balamurali (2015). See Abstract Title re Request for Hearing from Kremers Urban Pharmaceuticals, Inc. (Alston & Bird)",Supporting & Related Material,Reference (external attachments),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T19:21:11Z,,0,0,0900006482d154ce FDA-2016-N-3120-0449,FDA,FDA-2016-N-3120,"Reference 81 Modi et al (2000). See Abstract Title re Request for Hearing from Kremers Urban Pharmaceuticals, Inc. (Alston & Bird)",Supporting & Related Material,Reference (external attachments),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T19:32:06Z,,0,0,0900006482d154d1 FDA-2016-N-3120-0457,FDA,FDA-2016-N-3120,"Reference 89 Pera, G. (2011). What’s Up With Generic Concerta? re Request for Hearing from Kremers Urban Pharmaceuticals, Inc. (Alston & Bird)",Supporting & Related Material,Reference (external attachments),2017-12-27T05:00:00Z,2017,12,,,2017-12-27T19:48:35Z,,0,0,0900006482d154d9